Abstract
The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001).
Keywords: Neutralizing antibodies; S-RBD antibodies; SARS-CoV-2; Serological tests; Vaccines.
【저자키워드】 SARS-CoV-2, Vaccines, Neutralizing antibodies, Serological tests, S-RBD antibodies, 【초록키워드】 neutralizing antibody, antibodies, CLIA, ACE2, Vaccines, Neutralizing antibodies, antibody, disease severity, Antibody Response, hospitalized patients, Receptor binding domain, specificity, Viral, Serological tests, Serological assay, RBD, S-RBD, Patient, receptor, binding antibodies, asymptomatic patients, specific antibodies, Angiotensin-converting enzyme, hospitalized COVID-19 patient, Interaction, angiotensin, host cells, Serum level, Prevent, observé, defined, analyzed, carried, specific antibody, elevated, strongly related, 【제목키워드】 antibody, Infection, specificity, SARS-CoV-2 patient,